The spectrum of giant cell arteritis and polymyalgia rheumatica: Revisiting the concept of the disease

Rheumatology (United Kingdom)

Volumn 56, Issue 4, 2017, Pages 506-515

  Dejaco, Christian ^a   Duftner, Christina ^b   Buttgereit, Frank ^c   Matteson, Eric L ^d   Dasgupta, Bhaskar ^e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Mayo Clinic   (United States)

^e SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biological therapies; Diagnostic imaging; Giant cell arteritis; Immunosuppressants; Polymyalgia rheumatica; Vasculitis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; CYTOKINE; RADIOPHARMACEUTICAL AGENT;

ARTHRITIS; CELL MATURATION; CLINICAL FEATURE; DENDRITIC CELL; DISEASE CLASSIFICATION; DISEASE COURSE; ECHOGRAPHY; GENETIC ASSOCIATION; GIANT CELL ARTERITIS; HISTORY OF MEDICINE; HUMAN; MODERN TIMES; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; TEMPORAL ARTERITIS; AGED; COMPLICATION; DIFFERENTIAL DIAGNOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; PHYSIOLOGY; POLYMYALGIA RHEUMATICA; T LYMPHOCYTE;

AGED; CYTOKINES; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; GIANT CELL ARTERITIS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; POLYMYALGIA RHEUMATICA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; T-LYMPHOCYTES;

EID: 85017262843     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew273     Document Type: Review

References (112)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Dejaco C, Duftner C, Dasgupta B, Matteson EL, Schirmer M. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging Health 2011;7:633-45.
3. Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013;25:3-9.
4. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
5. Blockmans D, De Ceuninck L, Vanderschueren S et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007;46:672-7.
6. Moosig F, Czech N, Mehl C et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 2004;63:870-3.
7. Lavado-Pérez C, Martínez-Rodríguez I, Martínez-Amador N et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. Rev Esp Med Nucl Imagen Mol 2015;34:275-81.
8. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology 2008;47:96-101.
9. Schmidt WA, Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology 2002;41:46-52.
10. Stammler F, Ysermann M, Mohr W, Kuhn C, Goethe S. [Value of color-coded duplex ultrasound in patients with polymyalgia rheumatica without signs of temporal arteritis]. Dtsch Med Wochenschr 2000;125:1250-6.
11. Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131-7.
12. Horton B, Magath T, Brown G. An undescribed form of arteritis of the temporal vessels. Proc StaffMeet Mayo Clin 1932;7:700-1.
13. Paulley JW, Hughes JP. Giant-cell arteritis, or arteritis of the aged. Br Med J 1960;2:1562-7.
14. Hamrin B. Polymyalgia arteritica. Acta Med Scand Suppl 1972;533:1-131.
15. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
16. Salvarani C, Macchioni PL, Tartoni PL et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987;5:205-15.
17. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978;88:162-7.
18. Patil P, Williams M, Maw WW et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 2015;33(2 Suppl 89):S103-6.
19. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 2016;55:66-70.
20. González-Gay MA, Blanco R, Rodríguez-Valverde V et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504.
21. Wenkel H. [Bilateral amaurosis in 11 patients with giant cell arteritis confirmed by arterial biopsy]. Klin Monbl Augenheilkd 2001;218:658-61.
22. Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981;24:1414-8.
23. Liozon E, Boutros-Toni F, Ly K et al. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003;30:1272-6.
24. Alba MA, García-Martínez A, Prieto-González S et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine 2014;93:194-201.
25. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 2004;51:652-5.
26. Czihal M, Tató F, Förster S et al. Fever of unknown origin as initial manifestation of large vessel giant cell arteritis: diagnosis by colour-coded sonography and 18-FDG-PET. Clin Exp Rheumatol 2010;28:549-52.
27. González-Gay MA, García-Porrúa C, Vázquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5.
28. Tuckwell K, Collinson N, Klearman M, Dimonaco S, Stone JH. Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis [abstract]. Arthritis Rheumatol 2015;67 (Suppl 10), 1979.
29. Kermani TA, Warrington KJ, Cuthbertson D et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 2015;42:1213-7.
30. Berti A, Campochiaro C, Cavalli G et al. Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun Rev 2015;14:352-7.
31. Ninet JP, Bachet P, Dumontet CM et al. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med 1990;88:13-20.
32. Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 1988;38:685-9.
33. Bley TA, Warnatz K, Wieben O et al. High-resolution MRI in giant cell arteritis with multiple inflammatory stenoses in both calves. Rheumatology 2005;44:954-5.
34. Goupil de Bouillé J, Lecouffe-Desprets M, Bigot A et al. [Unilateral isolated Raynaud's phenomenon leading to diagnosis of multifocal giant-cell arteritis complicated with renal ischemia]. J Mal Vasc 2015;40:200-5.
35. Kermani TA, Crowson CS, Muratore F et al. Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? Semin Arthritis Rheum 2015;44:724-8.
36. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502-7.
37. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum 2004;51:274-7.
38. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
39. Kermani TA, Warrington KJ, Crowson CS et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989-94.
40. Pease CT, Haugeberg G, Morgan AW et al. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. J Rheumatol 2005;32:1043-6.
41. Narváez J, Estrada P, López-Vives L et al. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum 2015;45:328-33.
42. Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015;74:1799-807.
43. Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol 2015;67:2569-80.
44. Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999;42:1259-66.
45. Ceccato F, Roverano SG, Papasidero S et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006;12:167-71.
46. Salvarani C, Cantini F, Macchioni P et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998;41:1221-6.
47. Gómez Huelgas R, San Román Terán CM, Juárez Ferná ndez C. [RS3PE syndrome as presenting form of giant cell arteritis]. Rev Clínica Española 2002;202:361-2.
48. Cantini F, Salvarani C, Olivieri I et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis 1999;58:230-6.
49. Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol 2000;18:S53-5.
50. Dasgupta B, Cimmino MA, Kremers HM et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012;64:943-54.
51. Caporali R, Montecucco C, Epis O et al. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis 2001;60:1021-4.
52. Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992;19:270-2.
53. Takahashi H, Yamashita H, Kubota K et al. Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol 2015;25:546-51.
54. Yamashita H, Kubota K, Takahashi Y et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and largevessel vasculitis. Mod Rheumatol 2012;22:705-11.
55. Marzo-Ortega H, Rhodes LA, Tan AL et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis Rheum 2007;56:3496-501.
56. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
57. Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010;69:263-9.
58. Dejaco C, Klotz W, Larcher H et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:R119.
59. Cutolo M, Montecucco CM, Cavagna L et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006;65:1438-43.
60. Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
61. van der Geest KSM, Abdulahad WH, Chalan P et al. Disturbed B cell homeostasis in patients with newlydiagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 2014;66:1927-38.
62. Mackie SL, Taylor JC, Haroon-Rashid L et al. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Res Ther 2015;17:195.
63. Salvarani C, Boiardi L, Mantovani V et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999;58:303-8.
64. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994;37:514-20.
65. Martínez-Taboda VM, Bartolome MJ, Lopez-Hoyos M et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum 2004;34:454-64.
66. Combe B, Sany J, Le Quellec A, Clot J, Eliaou JF. Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 1998;25:94-8.
67. Carmona FD, González-Gay MA, Martín J. Genetic component of giant cell arteritis. Rheumatology 2014;53:6-18.
68. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013;9:731-40.
69. Ma-Krupa W, Jeon M-S, Spoerl S et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;199:173-83.
70. Krupa WM, Dewan M, Jeon M-S et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002;161:1815-23.
71. Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-20.
72. Hernández-Rodríguez J, García-Martínez A, Casademont J et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002;47:29-35.
73. Cavazza A, Muratore F, Boiardi L et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol 2014;38:1360-70.
74. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-15.
75. Chatelain D, Duhaut P, Loire R et al. Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica? Arthritis Rheum 2008;58:2565-73.
76. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
77. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008;118:1276-84.
78. Deng J, Ma-Krupa W, Gewirtz AT et al. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res 2009;104:488-95.
79. Kluger MA, Melderis S, Nosko A et al. Treg17 cells are programmed by Stat3 to suppress Th17 responses in systemic lupus. Kidney Int 2016;89:158-66.
80. Bending D, De la Peña H, Veldhoen M et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009;119:565-72.
81. Ciccia F, Rizzo A, Guggino G et al. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology 2015;54:1596-604.
82. Roblot P, Morel F, Lelievre E et al. Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy. J Rheumatol 1996;23:408-10.
83. Straub RH, Herfarth HH, Rinkes B et al. Favorable role of interleukin 10 in patients with polymyalgia rheumatica. J Rheumatol 1999;26:1318-25.
84. Samson M, Audia S, Fraszczak J et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012;64:3788-98.
85. Meliconi R, Pulsatelli L, Uguccioni M et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996;39:1199-207.
86. Dejaco C, Duftner C, Al-Massad J et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 2013;72:1852-9.
87. Dejaco C, Duftner C, Klauser A, Schirmer M. Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica. Rheumatol Int 2010;30:297-303.
88. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997;337:1336-42.
89. Aschwanden M, Kesten F, Stern M et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 2010;69:1356-9.
90. Diamantopoulos AP, Haugeberg G, Hetland H et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 2014;66:113-9.
91. Nesher G, Shemesh D, Mates M, Sonnenblick M, Abramowitz HB. The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. J Rheumatol 2002;29:1224-6.
92. Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and followup of suspected cases of temporal arteritis. Clin Rheumatol 2012;31:231-7.
93. Karahaliou M, Vaiopoulos G, Papaspyrou S et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 2006;8:R116.
94. Bley TA, Weiben O, Uhl M et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005;52:2470-7.
95. Bley TA, Uhl M, Carew J et al. Diagnostic value of highresolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 2007;28:1722-7.
96. Klink T, Geiger J, Both M et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 2014;273:844-52.
97. Geiger J, Bley T, Uhl M et al. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging 2010;31:470-4.
98. Siemonsen S, Brekenfeld C, Holst B et al. 3T MRI reveals extra-and intracranial involvement in giant cell arteritis. Am J Neuroradiol 2014;36:91-7.
99. Koenigkam-Santos M, Sharma P, Kalb B et al. Magnetic resonance angiography in extracranial giant cell arteritis. J Clin Rheumatol 2011;17:306-10.
100. Schmidt WA, Krause A, Schicke B, Kuchenbecker J, Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology 2009;48:383-5.
101. Al-Louzi O, Hauptman H, Saidha S. Biopsy-negative PETpositive giant-cell arteritis. Neurology 2014;83:1674-6.
102. Alpert JN, Saidha S, Al-Louzi O. Biopsy-negative PETpositive giant-cell arteritis. Neurology 2015;85:743.
103. Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010;11:44.
104. Soussan M, Nicolas P, Schramm C et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine 2015;94:e622.
105. Bley TA, Reinhard M, Hauenstein C et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008;58:2574-8.
106. Both M, Ahmadi-Simab K, Reuter M et al. MRI and FDGPET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis 2008;67:1030-3.
107. Förster S, Tato F, Weiss M et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa 2011;40:219-27.
108. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23.
109. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010;49:1594-7.
110. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186-90.
111. Salvarani C, Cantini F, Niccoli L et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33-8.
112. Cantini F, Salvarani C, Olivieri I et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.